ASTRAZENECA PLC Form 6-K July 11, 2013

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of July 2013

Commission File Number: 001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F X Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82

Edgar Filing: ASTRAZENECA PLC - Form 6-K

TR - 1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Astrazeneca Plc

2. Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights

Yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation:

Legal & General Group Plc (L&G)

4. Full name of shareholder(s) (if different from 3.):

N/A

5. Date of the transaction and date on which the threshold is crossed or reached:

09 July 2013

6. Date on which issuer notified:

10 July 2013

7. Threshold(s) that is/are crossed or reached:

L&G (Below 3%)

8. Notified details:

A: Voting rights attached to shares

Class/type of Situation previous shares to the triggering

transaction

Resulting situation after the triggering transaction

Edgar Filing: ASTRAZENECA PLC - Form 6-K

if possible % of voting rights Number Number Number of voting of of using Number rights the ISIN Shares Voting of shares Direct Indirect Direct Indirect **CODE Rights** 57,366,432 **Ordinary USD** Below 3%

0.25 (As on 05/08/2010)

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial Expiration Exercise/ Conversion

Type of finalicial Expiration Exercise/ Conversion

instrument date Period

Number of voting rights

that may be acquired if the % of voting rights

instrument is exercised/

converted.

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments Resulting situation after the triggering transaction

Type of financialExerciseExpirationExerciseConversionNumber of voting rights% of voting rights instrument price date period instrument refers to

Nominal Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

Below 3%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Legal & General Group Plc (Direct and Indirect) (Group)

Legal & General Investment Management (Holdings) Limited (LGIMH)

(Direct and Indirect)

Legal & General Investment Management Limited (Indirect) (LGIM)

Legal & General Group Plc (Direct) (L&G) (Below 3% = LGAS, LGPL & PMC)

Legal & General Investment Management Legal & General Insurance Holdings Limited (Direct)

(Holdings) Limited (Direct) (LGIMHD) (LGIH)

Legal & General Assurance (Pensions Legal & General Assurance Society Limited (LGAS &

Management) Limited (PMC) LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Proxy Voting:

10. Name of the proxy holder: N/A

11. Number of voting rights proxy holder will cease to

hold:

12. Date on which proxy holder will cease to hold voting

rights:

N/A

N/A

13. Additional information:

Notification using the total voting rights figure of

1,252,224,261

14. Contact name: Angela Hayter (LGIM)

15. Contact telephone number: 020 3124 3851

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 11 July 2013 By: /s/ Adrian Kemp

Name: Adrian Kemp Title: Company Secretary